ArticleEvidence-based complementary and alternative medicine : eCAM2010
AMP N(1)-oxide, a unique compound of royal jelly, induces neurite outgrowth from PC12 cells via signaling by protein kinase A independent of that by mitogen-activated protein kinase.
Article in Evidence-based complementary and alternative medicine : eCAM, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Effect of Memo®, a natural formula combination, on Mini-Mental State Examination scores in patients with mild cognitive impairment.Clinical interventions in aging · 2013Trial
- Royal jelly a promising therapeutic intervention and functional food supplement: A systematic review.Heliyon · 2024Review
- Royal Jelly: Biological Action and Health Benefits.International journal of molecular sciences · 2024Review
- Royal jelly: a predictive, preventive and personalised strategy for novel treatment options in non-communicable diseases.The EPMA journal · 2023Review
- Effects of the royal jelly consumption on post-stroke complications in patients with ischemic stroke: results of a randomized controlled trial.Frontiers in nutrition · 2023Article
- Royal Jelly as an Intelligent Anti-Aging Agent-A Focus on Cognitive Aging and Alzheimer's Disease: A Review.Antioxidants (Basel, Switzerland) · 2020Review
- Royal Jelly-A Traditional and Natural Remedy for Postmenopausal Symptoms and Aging-Related Pathologies.Molecules (Basel, Switzerland) · 2020Review
- Composition of Royal Jelly (RJ) and Its Anti-Androgenic Effect on Reproductive Parameters in a Polycystic Ovarian Syndrome (PCOS) Animal Model.Antioxidants (Basel, Switzerland) · 2020Article
- Article
- New Insights into the Biological and Pharmaceutical Properties of Royal Jelly.International journal of molecular sciences · 2020Review
- Apitherapy for Parkinson's Disease: A Focus on the Effects of Propolis and Royal Jelly.Oxidative medicine and cellular longevity · 2020Review
- Royal Jelly and Its Components Promote Healthy Aging and Longevity: From Animal Models to Humans.International journal of molecular sciences · 2019Review
- Royal Jelly Alleviates Cognitive Deficits and β-Amyloid Accumulation in APP/PS1 Mouse Model Via Activation of the cAMP/PKA/CREB/BDNF Pathway and Inhibition of Neuronal Apoptosis.Frontiers in aging neuroscience · 2018Article
- Royal Jelly Reduces Cholesterol Levels, Ameliorates Aβ Pathology and Enhances Neuronal Metabolic Activities in a Rabbit Model of Alzheimer's Disease.Frontiers in aging neuroscience · 2018Article
- Royal jelly facilitates restoration of the cognitive ability in trimethyltin-intoxicated mice.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Lifespan-extending effects of royal jelly and its related substances on the nematode Caenorhabditis elegans.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Earlier we identified adenosine monophosphate (AMP) N(1)-oxide as a unique compound of royal jelly (RJ) that induces neurite outgrowth (neuritegenesis) from cultured rat pheochromocytoma PC12 cells via the adenosine A(2A) receptor. Now, we found that AMP N(1)-oxide stimulated the phosphorylation of not only mitogen-activated protein kinase (MAPK) but also that of cAMP/calcium-response element-binding protein (CREB) in a dose-dependent manner. Inhibition of MAPK activation by a MEK inhibitor, PD98059, did not influence the AMP N(1)-oxide-induced neuritegenesis, whereas that of protein kinase A (PKA) by a selective inhibitor, KT5720, significantly reduced neurite outgrowth. AMP N(1)-oxide also had the activity of suppressing the growth of PC12 cells, which correlated well with the neurite outgrowth-promoting activity. KT5720 restored the growth of AMP N(1)-oxide-treated PC12 cells. It is well known that nerve growth factor suppresses proliferation of PC12 cells before causing stimulation of neuronal differentiation. Thus, AMP N(1)-oxide elicited neuronal differentiation of PC12 cells, as evidenced by generation of neurites, and inhibited cell growth through adenosine A(2A) receptor-mediated PKA signaling, which may be responsible for characteristic actions of RJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.